Evidence map›Paper›PMID 40444990›Full record

ArticleJournal of virology2025

Assessing the fitness of Epstein-Barr virus following its reactivation.

Yen-Fu Adam Chen, Bianca Mocanu, Ezgi Akidil, Dagmar Pich, Josef Mautner, Bill Sugden, Wolfgang Hammerschmidt

Abstract read
In one paragraph

Article in Journal of virology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Yen-Fu Adam ChenEBV Vaccine Development, Helmholtz Zentrum München, German Research Center for Environmental Health, Munich, Germany.ORCID 0000-0003-1410-7645
Bianca MocanuEBV Vaccine Development, Helmholtz Zentrum München, German Research Center for Environmental Health, Munich, Germany.ORCID 0000-0002-4044-4277
Ezgi AkidilEBV Vaccine Development, Helmholtz Zentrum München, German Research Center for Environmental Health, Munich, Germany.ORCID 0000-0001-6873-1916
Dagmar PichEBV Vaccine Development, Helmholtz Zentrum München, German Research Center for Environmental Health, Munich, Germany.ORCID 0000-0001-7653-2327
Josef MautnerEBV Vaccine Development, Helmholtz Zentrum München, German Research Center for Environmental Health, Munich, Germany.ORCID 0000-0002-8680-1065
Bill SugdenMcArdle Laboratory for Cancer Research, University of Wisconsin-Madison, Madison, Wisconsin, USA.ORCID 0000-0002-8724-4504
Wolfgang HammerschmidtEBV Vaccine Development, Helmholtz Zentrum München, German Research Center for Environmental Health, Munich, Germany.ORCID 0000-0002-4659-0427

Funding

Visualizing EBV and HCMV DNA Dynamics During InfectionP01CA022443 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI Paul F. Lambert · 1985 to 2026
$53.1M
NCI NIH HHS P01 CA022443
6 · The paper itself

Abstract

Epstein-Barr virus (EBV) is usually maintained latently on passaging in cell culture, as are most herpesviruses

Indexed as

Epstein-Barr Virus InfectionsGenetic FitnessHerpesvirus 4, HumanVirus ActivationB-LymphocytesCell LineHumansVirus LatencyVirus ReplicationEBVEpstein-Barr virusfusion assayherpesvirusinfectionmutagenesisphysical particlesviral fitnessvirus titer

Identifiers

PMID40444990
PMCPMC12282151

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.